ANI Pharmaceuticals (ANIP) reported Q3 CY2025 results exceeding expectations, with revenue up 53.6% to $227.8 million. Full-year revenue guidance increased to $863.5 million. Cortrophin Gel drove growth, doubling net revenue. New patient starts and prescriber adoption were strong. Future growth will focus on Rare Disease products and generics. Challenges with ILUVIEN are expected to recover in 2026. Management highlighted increased investment in clinical evidence. Analysts will monitor Cortrophin Gel adoption, ILUVIEN recovery, and generics competition. ANIP stock currently trades at $91.35. US-China trade tensions have impacted stocks, but strong bank earnings are fueling a rebound. StockStory is hiring equity analysts and marketers.

Read more at Stock Story: Rare Disease Momentum and Generics Expansion Drive Upgraded Outlook